Parabilis Medicines plans to present updated zolucatetide clinical data from its ongoing study in desmoid tumor patients at ESMO Congress 2026. The oral session, scheduled for October 24 in Madrid, gives investors a dated event for the company’s planned data update and the program’s next public presentation.
Key Highlights
- The data concern zolucatetide in patients with desmoid tumors enrolled in an ongoing study.
- Thomas Kotarakos signed the report as chief financial officer on September 15, 2026.
- Parabilis Medicines intends to give an oral presentation at the ESMO Congress 2026.
- The presentation will cover updated clinical data from the ongoing zolucatetide study in desmoid tumor patients.
Parabilis Medicines, Inc. (NASDAQ: PBLS) is updating its guidance to reflect an intended oral presentation at the ESMO Congress 2026. The presentation will cover updated clinical data from an ongoing study of zolucatetide in desmoid tumor patients.
Zolucatetide Data Set for Sarcoma Session
Zolucatetide is being studied in patients with desmoid tumors. The clinical study remains ongoing, and Parabilis Medicines plans to present updated data from that work. The company has designated the update for an oral presentation rather than a written disclosure. The session is focused on sarcoma research and is classified as a Proffered Paper session. ESMO Congress 2026 is being held in Madrid, Spain.
October Presentation Provides Scheduled Data Milestone
It will begin in the morning in the Eastern time zone and later in the day in Central European Summer Time. Parabilis Medicines identified the event as the setting for its planned clinical-data update. Thomas Kotarakos, the company’s chief financial officer, signed the report on September 15, 2026.
FAQs
Q: When will Parabilis Medicines present zolucatetide data at ESMO?
A: Parabilis Medicines plans to present updated zolucatetide clinical data during an October presentation at ESMO Congress 2026. The presentation will take place in Madrid, Spain, but the article does not provide an exact date.
Q: What is Parabilis Medicines presenting to investors at ESMO Congress 2026?
A: Parabilis Medicines is presenting an update from its ongoing clinical study of zolucatetide in patients with desmoid tumors. The company has designated the update for an oral presentation in a Proffered Paper session focused on sarcoma research.
Q: Who signed Parabilis Medicines’ September 15, 2026 report?
A: Thomas Kotarakos signed Parabilis Medicines’ report on September 15, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.